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SUMMARY 
Platelet MAO activity was estimated in 60 male drug free schizophrenics and 26 controls matched for age. The paranoid 
group had significantly lower enzyme activity than the non-paranoid group and controls. Patients with premorbid schizoid 
personality had significantly lower enzyme activity than patients with non-schizoid premorbid personality and controls. A 
significant negative correlation between platelet MAO activity and severity and duration of illness was observed. Family 
history of schizophrenia, presence of auditory hallucinations and type and age of onset of illness were not related to 
platelet MAO activity. 
It has been suggested that platelet 
monoamine oxidase (MAO) activity could be 
a genetic marker for vulnerability to 
schizophrenics (Wyatt et al., 1973). Most 
studies show reduced platelet MAO activity in 
chronic schizophrenic patients but the 
deviations from control values have varied 
from study to study (Wyatt et al., 1979). 
Although extraneous factors such as diet, 
hospitalization and hormonal status cannot 
adequately account for this variation, 
biological heterogenity has been offered as a 
source of variability across studies (Wyatt et 
al., 1979). 
A point of interest has been the evidence 
that certain clinical features of schizophrenia -
auditory hallucinations, paranoid symptoms, 
intensity and duration of illness (Wyatt et al., 
1979) and global prognostic score (Gruen et 
al., 1982) may be related to platelet MAO 
activity. 
This study was undertaken to find out the 
relationship between clinical features - type 
and age of onset of illness, premorbid schizoid 
personality, family history of schizophrenia 
and duration and intensity of illness, and 
platelet MAO (MAO - B subtype) activity in 
schizophrenia. 
Material and Methods 
Patient group 
60 male schizophrenics between 16-50 
years of age (mean 27-± 8.56), diagnosed as 
per DSM-III criteria (American Psychiatric 
Association, 1980) independently by two 
psychiatrists, were selected from the out -
patient section of the University Hospital, 
Banaras Hindu University, Varanasi. These 
patients had no history of drug intake in the 
past 2 weeks, of receiving ECT in the past 6 
months or of drug addiction (alcohol, 
cannabis, opium etc.) and did not have any 
accompanying illness (ncuro - psychiatric 
disorder, anaemia, hypertension, migraine or a 
physical illness requiring treatment). In 
addition, none of the patient had a past or 
family history in their first degree relatives of 
an affective or schizoaffective illness. 
Control group 
30 male, normal age matched (mean 27.57± 
9.69 years) healthy volunteers were selected 
from the blood donors attending the Blood 
Bank of the University Hospital, B.H.U., 
Varanasi. These subjects did not have a 
histroy of drug addiction or a neuropsychiatric 
illness (schizophrenia, affective disorder, 
schizoaffective disorder, migraine, 
Huntington's chorea etc.) in themselves or 
their first degree relatives. 
Proopdure 
The patients were hospitalized and kept drug 
free till the next day when blood was collected 
for enzyme estimation. Details of psychiatric 
history and mental status examination were 
recorded on a structured proforma within 2 
days of hospitalization. Diagnosis of past and 
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family history was made according to DSM -
III criteria. Premorbid personality was 
assessed by the Schizoid - Non-schizoid scale 
of Gittleman - Klien and Klien (1969) and the 
patients were rated on the Brief Psychiatric 
Rating Scale (BPRS) (Overall and Gorham, 
1962) for the severity of symptoms. Patients 
were categorised into paranoid and 
non-paranoid group according to the presence 
or absence of paranoid features 
(suspiciousness, grandiosity, persecutory 
delusions, hostility, rigidity and emotional 
distance). 
20ml of fasting venous blood was collected 
between 9-11 AM from each subject through 
venepuncture in heparinized polypropylene 
tubes, and immediately placed in ice. Platelet 
protein was estimated by Lowery's method 
(Lowery et al., 1951). Finally, platelet MAO 
activity was estimated by Radio-Isotopic 
technique using 14C Tryptamine Bisuccinate 
as the substrate according to the procedure of 
Parvez and Parvez (1973). The method has 
been described in detail by Sharma et al. 
(1990). 
All the estimations were done in duplicate 
and the mean taken. Enzyme activity was 
expressed in nanomoles/mg protein/hour (n 
mol/mg protein/h). The laboratory personnel 
were blind to the identity of the sample. 
Recent findings suggest that very low and 
very high platelet MAO activity is associated 
with personality profiles linked with 
vulnerability to various psychiatric disorders 
and the group with intermediate enzyme 
activity is presumably more normal (Schalling 
et al., 1987). Platelet MAO activity in the 
healthy control group ranged from 9.5-0.5 n 
mol/mg protein/h. The subjects with platelet 
MAO activity in the upper and lower decile 
were excluded so that 26 controls were 
available for final analysis. The data was 
analysed by student T test and analysis of 
variance. 
Results 
The mean platelet MAO activity in the 
patient group was 3.40+ 2.06 (range 0.31± 
8.11) and that in the control subjects was 
4.06+ 1.16 (range 1.94± 6.89) n 
mol/mg/protein/h. Although enzyme activity 
in the patients was lower than that in controls, 
the difference was not statistically significant 
(t=1.68; d.f.=84). 
10 patients had received neuroleptic 
medication for variable periods ( 3 month -
* ll yr) but were drug free at the time of their 
inclusion in the study. There was no 
significant difference (t=0.73, df=58) in the 
platelet MAO activity of treated (N=10; 3.79 
± 2.2 n mol/mg protein/h) and untreated 
patients (N=50; 3.21+ 2.04 n mol/mg 
protein/h). 
Platelet MAO activity in chronic 
schizophrenics (N=13; 2.75± 1.99 n 
mol/mg/protein/h) was significantly lower 
(t=2.19; p <0.05; d.f.=37) than enzyme 
activity in control subjects. Although platelet 
MAO activity was lower in the chronic 
schizophrenics compared to sub-chronic 
schizophrenics (N=47, 3.58+ 2.07 n mol/mg 
protein/h), the difference was not statistically 
significant 
Enzyme activity did not differ significantly 
(F=2.79; N.S.) between patients with family 
history of schizophrenia (N=9; 2.4Q+ 1.15 n 
mol/mg protein/h), patients without family 
history of schizophrenia (N=51, 3.58± 2.15 n 
mol/mg portein/h) and controls. 
14 patients presented with auditory 
hallucinations and 46 patients did not present 
with these symptoms. The enzyme activity did 
not differ (F=2.52, N.S.) between the 
hallucinatory (2.71± 1.53 n mol/mg protein/h) 
and non-hallucinatory groups (3.77+ 2.68 n 
mol/mg protein/h) and controls. 
The paranoid group had significantly lower 
enzyme activity than the non-paranoid group 
and controls (Table-1). 
Schizophrenics with premorbid schizoid 
personality had significantly lower enzyme 
activity than those with non-schizoid 
premorbid personality and controls (Table-2). 
Table-1 Platelet MAO activity in paranoid and 
non-paranoid groups of schizophrenia 
PlaldetMAO 
Mean 
SJ). 
activity 
Paranoid 
(n=17) 
125 
1.097 
Non-Paranoid 
M5) 
3.85 
219 
Contra 
(n=26 
4.06 
1.16 
F-6.38.JX0.01 
Paranoid vs Non-Paranoid : t=2.85, df-58;p<0.01 
Paranoid vs Control: t=5.73, df=41, pc.001 
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TMble-2 Comparison of MAO activity In patients with 
schlzold/non- schizoid premorbid personality 
Schizoid 
PMP 
(n-37) 
Platelet MAO activity 
Mean Z96 
S.D. 1.76 
Non-schizoid 
PMP 
(n-23) 
4.12 
2.35 
Controls 
(n-26) 
4.06 
1.16 
F-4.14,p<0.025 
Schiz. vs Non-schizoid : t-4.31; df-58, pcOOl 
Schiz. vs Controls: t-2.76;df-61,p<0.01 
Non-schiz-vs Controls : 1-0.08; df-47; N.S. 
Table-3 Correlation between platelet MAO aclvlty 
with Intensity of symptoms and duration of Illness 
Variables  12" 
Platelet MAO in patients 
(Mean-3.40; S.D.-2.06 
BPRS of schiz. patient 
(Mean-46.43; S.D.-6.55) 
Duration of illness (Yrs) 
(Mean-1.76; S.D.-2.22) 
-0.32* 0.10 
[*p<.05.**p<.001] 
The severity of illness, measured by the 
total BPRS score, and duration of illness in 
the patients (range 6 mon-11 yrs) correlated 
negatively with platelet MAO activity 
(Table-3). 
Table-4 Comparison of paranoid and non-paranoid 
groups on schizoid/non-schlzold premorbid 
personality and Intensity and duration of Illness 
Paranoid 
group 
(N-17) 
Non-paranoid 
group 
(N-43) 
Premorbid personality 
Schizoid 
Non-schizoid 
11 26 
6 17 
x
2-0.08,d.f.-X,N.S. 
Intensity of 
illness 
(Total B.P.R.S. score) 
4816.14  45.95±6.84 
1-1.07, d.f.-58.N.S. 
Duration of illness 1.85± 1.88 1.72±Z36 
(in Yrs) 
t-0.2, d.f.-58, N.S. 
There was no significant difference between 
the paranoid and non-paranoid groups with 
regard to schizoid premorbid personality, 
intensity and duration of symptoms (Table-4). 
Discussion 
The present investigation was an attempt to 
clarify the relationship between platelet MAO 
activity and certain clinical features of 
schizophrenia. Platelet MAO activity was 
observed to be lower in the paranoid group 
when compared to the nonparanoid group and 
controls. The two groups of patients were 
comparable on clinical variables. Schizoid 
premorbid personality, intensity and duration 
of illness were found to be related with 
enzyme activity. These observations are in 
conformity to several reports (Schildkraut et 
al., 1975; Sullivan et al., 1978) and suggest 
that the paranoid patients may form a 
sub-group with low platelet MAO activity. 
Some investigators could not find a significant 
difference between paranoid and non-paranoid 
schizophrenics (Berger et al., 1978 ; Freidhoff 
et al., 1978 ; Trivedi et al., 1987). 
Patients with premorbid schizoid 
personality were observed to have 
significantly lower activity than those who 
were premorbidly non-schizoid. A positive 
correlation between prognostic score and 
platelet MAO activity in chronic 
schizophrenics has been reported (Gruen et al., 
1982). Patients with premorbid schizoid 
personality were poor prognosis cases as 
schizoid personality has been reported to be a 
poor prognostic indicator (Slater and Roth, 
1980). Thus, lowered enzyme activity in this 
group is understandable. There is a need to 
prospectively validate the prognostic utility of 
the platelet MAO levels in schizophrenia, 
using follow up studies. 
Of particular interest was the finding of an 
inverse relationship between severity of 
illness, as measured by the BPRS, and platelet 
MAO activity (pCO.OOl).Thc former 
accounted for 36% of the variation in enzyme 
activity (r-0.36). There have been reports 
(Wyatt et al., 1973; Becker and Shaskan, 
1977; Cookson et al., 1975) in which similar 
observations have been made. Cookson et al. 
(1975) observed changes in platelet MAO 
activity which paralleled the mental state in a 
patient of schizophreniform psychosis. 
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activity has been reported in studies of acute 
than of chronic schizophrenic patients ( Wyatt 
et al.,1972), suggesting that chronicity of 
illness was observed to be a significant 
variable accounting for 10% (r^).l0) of the 
variance in enzyme activity of patients. A few 
workers ( Mann and Thomas, 1979; Trivedi 
et. al., 1987), however, did not observe a 
relation between severity and duration of 
illness and platelet MAO activity in chronic 
schizophrenics. 
Although chronicity may be associated with 
drug intake, it may be pointed out that the 
MAO values in medicated and unmedicated 
patients did not differ significantly. This 
finding reduces the likelihood that the results 
of the present investigation are largely drug 
related. Even though neuroleptic-induced 
reduction in enzyme activity has been reported 
(Takahashi et al., 1975; Friedhoff et al., 1978) 
the weight of evidence suggests that 
phenothiazines and butyrophenones, have, if 
anything, a tendency to increase platelet MAO 
activity (Wyatt et al., 1979). Furthermore, as 
the life span of platelet is about 9.9 days 
(Harker and Finch, 1969) it seems that a 2 
week drug free period is sufficient for a study 
of platelet MAO activity. 
It would have been desirable to analyse 
MAO activity in relation to dose and different 
medications. However, the medicated subjects 
had been treated with different combinations 
and doses of neuroleptic drugs for variable 
periods of time. The variability did not allow a 
meaningful analysis of differential drug 
effects on enzyme activity. 
The findings of the present study are at 
variance with some others, possibly because 
of differences in diagnostic criteria 
(Schildkraut et al., 1976; Becker and Shaskan, 
1977; Potkin et al., 1978; Berger et al., 1978; 
Friedhoff et al., 1978, Bond et al., 1979; 
Trivedi et al., 1987) and assay procedures 
(Potkin et al., 1978; Bond et al., 1979; Trivedi 
et al., 1987). Whereas some investigators 
studied chronic schizophrenics (Berger et al., 
1978; Trivedi et al., 1987) diagnosed as per 
RDC or DSM-II criteria, others investigated 
acute schizophrenics (Bond et al., 1979) or 
mixed populations of patients (Potkin et al., 
1978; Friedhoff et al., 1978). Patients of the 
present study were diagnosed according to 
DSM-III criteria which includes sub-chronic 
and chronic forms of schizophrenia. 
The work of Berger and co-workers (Berger 
et al., 1978) involved the study of chronic 
schizophrenics, most of them receiving 
neuroleptics for long periods and hospitalized 
for over a year. Others have relied on hospital 
records (Schildkraut et al., 1976; Berger et al., 
1978), a less reliable source of data. 
Platelet MAO activity has been reported to 
be higher in females and to fluctuate during 
the pre and post-ovulatory phases (Wyatt et 
al., 1979). Thus, the findings reported by 
some workers (Friedhoffet. al., 1978; Bond et 
al., 1979 ) are questionable since they 
involved small samples with patients of both 
sexes and did not control for the phase of 
menstrual cycle. The population of this study 
hence was restricted to male patients. 
In the presence of biological heterogeneity 
(Wyatt et al., 1979; Baron et al., 1984), the 
discrepant results across studies may represent 
a variable representation of genetic (i.e. low 
MAO values) versus non- genetic (i.e. normal 
MAO values) types of schizophrenia. The 
findings reported should be regarded as 
tentative. It would be neccessary to replicate 
the work on female patients as well. 
The present data show that specific clinical 
features of the schizophrenic illness, severity 
and duration of illness, presence of paranoid 
features and premorbid schizoid personality 
may be related to platelet MAO activity and 
can account, in part, for the discrepant results 
obtained across studies. There are indications 
that the relationship between platelet MAO 
activity and schizophrenia is complex. Further 
work should involve the study of other factors 
in relation to platelet MAO activity, 
particularly those that have been shown to 
have prognostic significance. 
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